Effects of paclitaxel (with albumin) injection: A Synthesis of Findings from 20 Studies

  1. Home
  2. Effects of paclitaxel (with albumin) injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of paclitaxel (with albumin) injection: A Synthesis of Findings from 20 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of paclitaxel (with albumin) injection: A Synthesis of Findings from 20 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Numerous studies have shown that paclitaxel, a chemotherapy drug, is effective in treating various cancers, but it suffers from poor solubility, which hinders its clinical application. Recent research has focused on developing new paclitaxel formulations to improve its delivery and reduce side effects. 19 .

One approach involves using albumin-bound paclitaxel (nab-paclitaxel), a novel formulation that has demonstrated greater antitumor activity and less toxicity than conventional paclitaxel formulations. 20 , 4 This formulation has been approved for the treatment of metastatic breast cancer in several countries. 4 In addition, nab-paclitaxel combined with gemcitabine has shown promising results in treating pancreatic cancer. 3 , 5

Another strategy involves encapsulating paclitaxel in nanoparticles, which can potentially improve drug delivery efficiency and extend its duration of action. 9 , 7 Furthermore, conjugating paclitaxel to proteins like albumin can enhance its stability in the bloodstream and target it to tumors. 11

Researchers are also exploring the use of ultrasound contrast agents loaded with paclitaxel for simultaneous diagnosis and therapy. 18 These agents can accumulate in tumors and enhance ultrasound signals, enabling early cancer detection. Additionally, they can directly deliver paclitaxel to the tumor, potentially increasing treatment efficacy.

Further research involves developing delivery systems using paclitaxel as a carrier to transport various anticancer drugs efficiently to tumors. 14 For instance, nanoparticles combining paclitaxel with photosensitizers have emerged as a promising approach for combined photodynamic and chemotherapy. 12 These nanoparticles can accumulate in tumors and, upon light irradiation, kill tumor cells.

Benefits and Risks

Benefits Summary

Paclitaxel formulations, particularly albumin-bound paclitaxel (nab-paclitaxel), have shown significant benefits in cancer treatment. They offer improved drug delivery efficiency, extended duration of action, and reduced side effects compared to conventional paclitaxel formulations. Nab-paclitaxel has been approved for treating metastatic breast cancer and has shown promising results in combination with gemcitabine for pancreatic cancer treatment.

Risks Summary

Paclitaxel, despite its effectiveness, can cause various side effects, including nerve damage, digestive issues, and suppression of bone marrow function. 20 , 4 Additionally, paclitaxel can cause birth defects if administered to pregnant women.

Comparison of Studies

Similarities in Studies

The majority of studies have consistently demonstrated that paclitaxel effectively inhibits tumor growth. Moreover, many studies highlight the advantages of novel paclitaxel formulations, such as albumin-bound paclitaxel or nanoparticle-based delivery, in terms of improved drug delivery and reduced side effects.

Differences in Studies

The effectiveness and side effects of paclitaxel can vary depending on factors like the administration method, dosage, and patient's condition. Additionally, there are several different paclitaxel formulations available, including conventional formulations, nanoparticle formulations, and albumin-bound formulations.

Consistency and Inconsistencies of Findings

While research findings regarding paclitaxel's effectiveness and side effects show consistency, achieving complete agreement is challenging due to variations in research methods, patient populations, and other factors. Further research is needed to enhance our understanding of paclitaxel's effects and side effects.

Considerations for Practical Applications

Paclitaxel can have significant side effects, so it is crucial for patients to follow their doctor's instructions carefully and be aware of potential side effects. Paclitaxel should not be administered to pregnant women because it can harm the developing fetus. Women who are considering pregnancy should consult with their doctor before using paclitaxel.

Limitations of Current Research

Despite the advancements in developing new paclitaxel treatment strategies, several challenges remain. Paclitaxel's effect on normal cells can lead to severe side effects, making treatment difficult. The effectiveness of paclitaxel can vary depending on individual patient characteristics and tumor types, and it may not be effective in all cases. Additionally, the development of resistance to paclitaxel is a significant concern.

Future Research Directions

Future research should focus on developing new strategies to enhance the effectiveness of paclitaxel while minimizing its side effects. This includes developing techniques for targeted delivery to tumor cells, identifying drugs that can overcome paclitaxel resistance, and exploring new drugs that can reduce paclitaxel-related side effects. Research on combination therapies involving paclitaxel with other anticancer drugs is also crucial.

Conclusion

Paclitaxel, a potent anticancer drug, has proven effective in treating various cancers, but its significant side effects present a challenge. Recent developments in paclitaxel formulations, including albumin-bound paclitaxel and nanoparticle delivery systems, have shown promising results in improving drug delivery and reducing side effects. Further research into these areas holds the potential to develop more effective and safer paclitaxel-based therapies for cancer patients. It is important to consult with a healthcare professional to understand the risks and benefits of paclitaxel treatment.

Literature analysis of 20 papers
Positive Content
19
Neutral Content
1
Negative Content
0
Article Type
1
0
0
2
20
1.

Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.

Author: BabalonisShanna, LofwallMichelle R, NuzzoPaul A, WalshSharon L

Pain relief
Abuse potential
Respiratory depression

Oxymorphone is a semisynthetic μ-opioid agonist marketed as a prescription analgesic. This study compared the pharmacodynamic effects of oxymorphone and oxycodone in opioid abusers. Oxymorphone was less potent than oxycodone on most pharmacodynamic measures, but at higher doses, its abuse liability was similar to oxycodone.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

2.

An injectable calcium phosphate cement for the local delivery of paclitaxel to bone.

Author: Lopez-HerediaMarco A, KamphuisG J Bernard, ThünePeter C, ÖnerF Cumhur, JansenJohn A, WalboomersX Frank

Treat bone metastases

This study investigated the use of calcium phosphate cement (CPC) as a local drug delivery system for chemotherapeutic agents. The study showed that CPC can effectively load and release paclitaxel, a chemotherapeutic agent, and that the released paclitaxel remains active to influence cell viability.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.

Author: FeliuJaime, Jorge FernándezMónica, MacarullaTeresa, MassutiBartomeu, AlberoAna, González GonzálezJosé Federico, Quintero-AldanaGuillermo, Delgado-MingoranceJuan Ignacio, Fernández MontesAna, García PiernaviejaCarmen, Valladares-AyerbesManuel, López MuñozAna María, Mondéjar SolísRebeca, VicentePilar, Casado GonzalezEsther, González CebriánIrene, López-VivancoGuillermo

Clinical response
Improved survival
Fatigue
Neutropenia

The combination of nab-paclitaxel and gemcitabine in an elderly population with pancreatic cancer improved survival and clinical response, but did not confirm a benefit in terms of quality-of-life.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.

Author: HoriuchiTakashi, UwagawaTadashi, ShiraiYoshihiro, SaitoNobuhiro, IwaseRyota, HarukiKoichiro, ShibaHiroaki, OhashiToya, YanagaKatsuhiko

Pancreatic cancer treatment

This study explores the potential of adding nafamostat mesilate (NM), an NF-κB inhibitor, to gemcitabine (GEM) and nab-paclitaxel (nPTX) chemotherapy for pancreatic cancer. Previous research has shown that NF-κB activation can cause chemoresistance, so adding NM to the regimen may increase the antitumor effect.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Author: SugaharaKazuki N, TeesaluTambet, KarmaliPriya Prakash, KotamrajuVenkata Ramana, AgemyLilach, GreenwaldDaniel R, RuoslahtiErkki

Enhanced efficacy
Improved drug penetration
Reduced side effects

This study explores the use of a tumor-penetrating peptide, iRGD, to enhance the delivery of anticancer drugs to tumors. iRGD improved the therapeutic index of various drugs, suggesting it may be a valuable tool for improving cancer therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

7.

Investigation on injectable, thermally and physically gelable poly(ethylene glycol)/poly(octadecanedioic anhydride) amphiphilic triblock co-polymer nanoparticles.

Author: LiangYanqin, QiaoYong, GuoShutao, WangLei, ZhaiYinglei, XieChaopeng, HuRenjie, DengLiandong, DongAnjie

Biocompatible
Drug delivery

A family of injectable, biodegradable, and thermosensitive co-polymer nanoparticle (NP) hydrogels based on mPEG-b-POA-b-mPEG was investigated for its ability to control drug release. The hydrogels showed sustained drug release and were non-toxic to normal mouse lung fibroblast cells.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.

Author: ChienAmy J, IlliJulie A, KoAndrew H, KornWolfgang M, FongLawrence, ChenLee-may, Kashani-SabetMohammed, RyanCharles J, RosenbergJonathan E, DubeySarita, SmallEric J, JahanThierry M, HyltonNola M, YehBenjamin M, HuangYong, KochKevin M, MoasserMark M

Cancer treatment

Chemotherapy often struggles to reach all cancer cells, limiting its effectiveness. This study investigates a new approach: using high doses of tyrosine kinase inhibitors (TKIs) to temporarily improve blood flow to tumors, allowing chemotherapy drugs to reach more cancer cells.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery.

Author: HackettMichael J, JoolakantiShyamsunder, HartranftMegan E, GuleyPatrick C, ChoMoo J

Cancer treatment
Drug solubility
Reduced side effects

This study presents a method for solubilizing paclitaxel (PTX) by conjugating it with a dicarboxylic fatty acid for specific binding to serum albumin. The resulting PDG derivative was less cytotoxic, slowly hydrolyzed to PTX, and exhibited improved pharmacokinetic properties compared to the TAXOL formulation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.

Author: KimHarrison, SamuelSharon, Lopez-CasasPedro, GrizzleWilliam, HidalgoManuel, KovarJoy, OelschlagerDenise, ZinnKurt, WarramJason, BuchsbaumDonald

Nab-paclitaxel, a nanoparticle formulation of paclitaxel, does not appear to be specifically targeted to SPARC-expressing tumor stroma, nor does it consistently reduce stroma density or increase tumor vascular perfusion.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

14.

Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy.

Author: ZhengKe, LiuHongyan, LiuXinxin, WangYing, LiLinlin, LiShijie, XueJinping, HuangMingdong

Enhanced antitumor effect

Albumin nanoparticles with combined functions of tumor targeting, chemotherapy and photodynamic therapy can highly enhance the anti-tumor effect.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

In vitro pyrogen test for toxic or immunomodulatory drugs.

Author: DaneshianMardas, GuentherArmin, WendelAlbrecht, HartungThomas, von AulockSonja

Drug safety
Pyrogenic contamination

This study describes a modification of the In vitro Pyrogen Test called AWIPT (Adsorb, Wash, In vitro Pyrogen Test) that improves the detection of pyrogenic contamination in injectable drugs, even in the presence of interfering additives.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

16.

In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.

Author: XiongXiang Yuan, GuoLiang, GongYan Chun, LiZi Ling, LiYu Ping, LiuZhi Yong, ZhouMing

Ovarian cancer treatment
Targeted drug delivery

Paclitaxel loaded in B-F127-PLA nanoparticles shows an initial burst release in the first 6 hours and followed by a slow release.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis.

Author: MurakamiMami, ErnstingMark J, UndzysElijus, HolwellNathan, FoltzWarren D, LiShyh-Dar

Enhanced antimetastatic effect
Reduced tumor volume

Cellax, a docetaxel-conjugate nanoparticle, selectively targets and depletes tumor stroma, leading to improved drug delivery and anti-metastatic effects. Compared to native docetaxel and nab-paclitaxel, Cellax shows a significant improvement in anti-tumor activity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Therapeutic Ultrasound Contrast Agents for the Enhancement of Tumor Diagnosis and Tumor Therapy.

Author: MoonHyungwon, YoonChanghan, LeeTae Woong, HaKyoung-Su, ChangJin Ho, SongTai-Kyong, KimKwangmeyung, KimHyuncheol

Early cancer diagnosis
Increased survival
Targeted drug delivery

Ultrasound microbubbles conjugated with paclitaxel-encapsulating human serum albumin nanoparticles enhanced echogenicity in breast cancer cells, enabling early cancer diagnosis and drug delivery for potential theragnosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Advances of paclitaxel formulations based on nanosystem delivery technology.

Author: LuoC, WangY, ChenQ, HanX, LiuX, SunJ, HeZ

Cancer treatment
Reduced paclitaxel toxicity

This paper provides an overview of recent advances in paclitaxel formulations based on nanosystems. These nanoformulations address paclitaxel's poor aqueous solubility and reduce its toxicities while enhancing its antitumor efficacy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

Albumin-bound paclitaxel (Abraxane) for advanced breast cancer.

Author:

Easier administration
Safer administration

This article highlights the development of a new formulation for a specific chemotherapy drug that aims to improve safety and ease of administration.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.